Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Subclinical Enthesitis in Psoriasis (INTERCEPT)
NCT04488185Phase 4Withdrawn
- Sponsor
- Novartis
- Start
- Nov 2020
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of secukinumab in plaque psoriasis, enthesitis, sponsored by Novartis. Planned start Nov 2020; status: withdrawn.
02
Drugs
secukinumab
03
Conditions
plaque psoriasisenthesitis
Beyond the preview
Go deeper on NCT04488185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04488185.